Jackson Thornton Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Jackson Thornton Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$208K	Sell	3,631 -534	-13%	-$29.3K	0.02%	392
2026 Q1	$227K	Sell	4,165 -30	-0.7%	-$1.75K	0.02%	254
2025 Q4	$252K	Sell	4,195 -2,897	-41%	-$158K	0.02%	248
2025 Q3	$388K	Buy	7,092 +2,103	+42%	+$120K	0.04%	132
2025 Q2	$289K	Buy	+4,989	New	+$294K	0.03%	85

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Jackson Thornton Wealth Management's BMRN Position: Q2 2026 in Review

Jackson Thornton Wealth Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 13% in Q2 2026, selling an estimated $29.3K and leaving 3,631 shares worth $208K. The position accounts for 0.02% of the portfolio, ranked #392.

Jackson Thornton Wealth Management first reported a position in BMRN in Q2 2025 and has held it in 5 quarters since. The position peaked at $388K in Q3 2025. 564 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Jackson Thornton Wealth Management held 3,631 shares of BioMarin Pharmaceuticals worth $208K as of Q2 2026.
Jackson Thornton Wealth Management sold 534 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $29.3K.
BioMarin Pharmaceuticals made up 0.02% of Jackson Thornton Wealth Management's portfolio in Q2 2026, its #392 holding.
Jackson Thornton Wealth Management first reported a position in BioMarin Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
Jackson Thornton Wealth Management's BioMarin Pharmaceuticals position peaked at $388K in Q3 2025.
564 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Jackson Thornton Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.